ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated (OTCBB: INSV), a company developing novel ophthalmic therapeutics, today announced that it will receive $489,000 under the U.S. Government’s Qualifying Therapeutic Discovery Project (“QTDP”) program. The grant was awarded in recognition of two clinical-stage programs, ISV-502, a product candidate being developed for the treatment of blepharitis, and ISV-303, a topical anti-inflammatory product intended to reduce the pain and inflammation associated with ocular surgery.
